Relmada Therapeutics (RLMD) Asset Utilization Ratio (2013)

Relmada Therapeutics (RLMD) posted quarterly Asset Utilization Ratio of 0.3 for Q4 2013, down 27.88% quarter-over-quarter from 0.41 in Q3 2013.

Analysis

Relmada Therapeutics (RLMD) Asset Utilization Ratio (2013) Analysis & Trends

Relmada Therapeutics (RLMD) has reported Asset Utilization Ratio for 1 consecutive years, with 0.3 the latest figure, recorded in Q4 2013.

In Q4 2013, Asset Utilization Ratio changed N/A year-over-year to 0.3; the TTM figure through Nov 2013 stood at 0.3 (changed N/A YoY), while the FY2013 annual figure was 0.27, changed N/A from the prior year.
Asset Utilization Ratio slipped to 0.3 in Q4 2013 per RLMD's latest filing, from 0.41 in the prior quarter.
Across five years, Asset Utilization Ratio topped out at 0.89 in Q2 2013 and bottomed at 0.3 in Q4 2013.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	0.47
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	0.38
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	0.20
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	0.69
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	0.90
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	0.13
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	0.54
10	Relmada Therapeutics	498.39 Mn	498.39 Mn	-	-

Historic Data

Download Data